Four-Pronged attack on liver cancer shows promise in trial
NCT ID NCT05532319
Summary
This study tested a combination of four treatments for advanced liver cancer that cannot be removed by surgery. The approach involved delivering chemotherapy directly to the liver, blocking the tumor's blood supply, and adding two drugs (lenvatinib and tislelizumab) that target the cancer and boost the immune system. The goal was to shrink tumors, control the disease, and help patients live longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, 530021, China
Conditions
Explore the condition pages connected to this study.